drug · antibody
trastuzumab biosimilar
pre_registrationupdated 5mo agoby EirGenix Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval38 co-mentions · 19 sources
- drugtrastuzumab emtansine28 co-mentions · 14 sources
- drugKADCYLA28 co-mentions · 14 sources
- drugtrastuzumab21 co-mentions · 21 sources
- drugONTRUZANT10 co-mentions · 5 sources
- companySamsung Bioepis Co Ltd5 co-mentions · 5 sources
- tagBreast Cancer2 co-mentions · 1 sources
- tagOncology2 co-mentions · 1 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 28 investigational indications.
indications
indications
Breast Cancer
targets
Receptor tyrosine-protein kinase erbB-2
all catalysts(0)
nothing on the calendar yet
Trials studying trastuzumab biosimilar
- phase2Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- phase1A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)
- —A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
News(10)
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 6d ago
- Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugsRoche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.fiercebiotech · 10d ago
- Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBioThrough its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.biospace · 1mo ago
- New Jazz cancer drug approval could drive blockbuster salesZiihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.biopharma_dive · 1mo ago
- A Spanish biotech banks $87M to make differentiated ADCsOna Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.biopharma_dive · 4mo ago
- Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerSacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.onclive · 4mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 4mo ago
- Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast CancerTreatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.onclive · 5mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 5mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 5mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that